Genomic Features of Response to Combination Immunotherapy in Lung Cancer

Publication date: 14 May 2018
Source:Cancer Cell, Volume 33, Issue 5
Author(s): Martin Früh, Solange Peters
In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.

Teaser

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.


https://ift.tt/2KpbfxL